AT13148 [1056901-62-2] [1056901-62-2]

Bioss

AT13148 [1056901-62-2] [1056901-62-2]

16

1056901-62-2

Research Use Only

Unconjugated

98 - 98.0

C17 H16 Cl N3 O

313.78

AT13148 is a novel oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity, which shows a distinct mechanism of action from other AKT inhibitors. AT13148 is currently being developed by Astex Pharmaceuticals. AT131148 was identified utilizing high-throughput X-ray crystallography and fragment-based lead discovery techniques. AT13148 caused substantial blockade of AKT, p70S6K, PKA, ROCK and SGK substrate phosphorylation and induction of apoptosis in both a concentration and time-dependent manner in cancer cells with clinically relevant genetic defects both in vitro and in vivo.

NC[C@@](O)(C1C=CC(Cl)=CC=1)C1C=CC(=CC=1)C1=CNN=C1

-20°C

12161509